Formycon Revises 2026 Adjusted EBITDA Guidance After Impairments
Formycon reported non-cash impairments of €39 million for FYB201 and €82 million for FYB202, citing increased competition and price pressure. It lowered adjusted EBITDA guidance to a range of -€15 million to -€5 million from the previous range of €5 million to €15 million. Revenue guidance of €60–70 million, EBITDA guidance of €0–10 million and year-end net working capital guidance of €20–30 million were maintained.
Formycon AG announced non-cash impairments of 39 million EUR for FYB201 (ranibizumab) and 82 million EUR for FYB202 (ustekinumab) due to increased competition and price pressure in their respective markets. Consequently, the company has revised its adjusted EBITDA guidance for fiscal year 2026 to a range of -15 million EUR to -5 million EUR, down from the previous range of 5 million EUR to 15 million EUR. The company maintained its guidance for revenue (60-70 million EUR), EBITDA (0-10 million EUR), and year-end net working capital (20-30 million EUR). Management plans to discuss these developments in detail during a conference call scheduled for November 12, 2026.